Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of Report (date of earliest event reported): October 26, 2017
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
|
| | | | |
Florida (State or other jurisdiction of incorporation) | | 001-35887 (Commission File Number) | | 26-2792552 (IRS Employer Identification No.) |
|
| | |
1775 West Oak Commons Ct, NE Marietta, GA (Address of principal executive offices) | | 30062 (Zip Code) |
(770) 651-9100
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
| |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
| |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
| |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
|
| |
Item 2.02 | Results of Operations and Financial Condition |
On October 26, 2017, MiMedx Group, Inc. (the “Company”) issued a press release announcing its financial results for the period ended September 30, 2017 and certain other matters. The release also announced that executives of the Company would discuss these results with investors on a conference call broadcast via the Company’s website located at www.mimedx.com and provided access information, date and time for the conference call. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Information contained on the Company's website is not incorporated by reference into this Current Report on Form 8-K.
The information provided pursuant to Item 2.02 of this Form 8-K is to be considered “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
|
| |
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(e) On October 26, 2017, the Board of Directors of the Company made the following awards of restricted stock to the Company’s named executive officers.
Parker H. “Pete” Petit, Chairman and Chief Executive Officer 12,500 shares
Bill Taylor, President 10,000 shares
Michael Senken, Chief Financial Officer 7,500 shares
Alexandra Haden, General Counsel 7,500 shares.
The awards vest one-third annually. The Committee determined to pay these awards in recognition of outstanding performance.
|
| |
Item 9.01 | Financial Statements and Exhibits |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | | |
Dated: | October 26, 2017 | MIMEDX GROUP, INC. | |
| | | |
| | | |
| | By: | /s/: Michael J. Senken | |
| | | Michael J. Senken, Chief Financial Officer | |